COMPREHENSIVE REVIEW OF MEDICATION-ASSISTED TREATMENT (MAT) FOR OPIOID USE DISORDER (OUD) IN THE ERA OF COVID–19
ENDURING RECORDED COURSE: Registration now open
Time of Enduring Recorded Course: One hour
This is the sixth module in a live webinar and enduring recorded course series on opioid addiction prevention. This module is designed to train and inform New Jersey health care professionals with prescribing authority, as well as mental health professionals, on the effectiveness of medication-assisted treatment (MAT) in treating opioid use disorder (OUD) in opioid treatment programs (OTPs), outpatient settings, and emergency room settings, in the era of COVID–19.
All participants who register for and complete this course will receive access to the New Jersey Opioid Medical Education Program Naloxone Distribution and Training Programs Guide. This comprehensive county-by-county guide, available in interactive and print formats for health care professional reference and patient education, includes pharmacies who dispense NARCAN® (naloxone hydrochloride) Nasal Spray and the recent FDA-approved generic naloxone hydrochloride nasal spray (utilizing standing orders, and via prescription). It also includes virtual trainings in the era of COVID–19 on how and when to use naloxone nasal spray.
All participants who register for and complete this course will also receive access to the New Jersey Opioid Medical Education Program COVID–19 Response Guide. This comprehensive guide, available in continually updated format for health care professional reference, includes changes to health care policies and practices with a focus on prescribing and telemedicine; harm reduction strategies for patients with opioid use disorder; considerations for special populations including individuals experiencing homelessness; supporting and protecting minority communities, with a focus on trauma-informed and culturally competent patient care; and guidance from specialty organizations.
Target Audience: Physicians, Physician Assistants, Podiatrists, Certified Nurse Midwives, Advanced Practice Nurses, Psychologists, Social Workers, Professional Counselors, Marriage and Family Therapists
Objectives: At the end of this activity, participants will be able to:
- Discuss trends and statistics specific to New Jersey concerning medication-assisted treatment (MAT) underutilization, and understand the origins and scientific development of MAT.
- Recognize differences between the three FDA-approved forms of MAT (methadone, buprenorphine, and naltrexone), making treatment decisions guided by effectiveness of modalities across the continuum of opioid use disorder (OUD) severity.
- Understand the importance of the Drug Addiction Treatment Act of 2000 (DATA 2000) in expanding access to buprenorphine from opioid treatment programs (OTPs) to office-based addiction treatment settings (OBATs), and the emergency room.
- Identify the flexibilities and waivers afforded to health care professionals prescribing MAT in the era of COVID–19.
- Outline how the prescribing of methadone and buprenorphine has changed with telemedicine, and how the delivery of methadone has expanded with federal guidance.
- Discuss changes to the behavioral health component of MAT in the era of COVID–19; referrals to counseling and access; and relaxation of the Health Insurance Portability and Accountability Act (HIPAA) enforcement and the 42 Code of Federal Regulations (CFR) Part 2 guidance during the pandemic.
- Identify solutions to overcome barriers to MAT and telemedicine for special populations, and solutions to overcome stigma surrounding patients with OUD, and those receiving MAT.
Available CME Credit for Physicians:
Rowan University School of Osteopathic Medicine (RowanSOM) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
RowanSOM designates this program for a maximum of 1 AOA Category 1-B credit and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
Rowan University School of Osteopathic Medicine (RowanSOM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
RowanSOM designates this Internet enduring activity for 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive full credit, you must be present for the enduring recorded course activity.
To receive a certificate of completion, and CME certificate, complete the Pre-Assessment, Post-Assessment, Knowledge Assessment, Attestation Form, and Outcome Survey/Evaluation.
Available CE Credit for Other Listed Health Care Professionals:
This enduring recorded course satisfies the statutory mandate that physician assistants, podiatrists, certified nurse midwives, nurses, psychologists, social workers, professional counselors, and marriage and family therapists obtain one credit in continuing education programs concerning prescription opioid drugs as a condition of licensure renewal. Upon successful completion of the enduring recorded course, participants will receive a certificate of completion, and should retain it in accordance with their relevant licensing board’s regulations.
To receive full credit, you must be present for the entire enduring recorded course activity.
All listed health care professionals must complete the Pre-Assessment, Post Assessment, and Knowledge Assessment to receive a certificate of completion.
All listed health care professionals must complete the Attestation Form, and Outcome Survey/Evaluation. Upon completion of these items, physicians will receive a CME certificate.
Hearing Impaired Registrants: This enduring recorded course will contain closed captioning.
For questions pertaining to AOA and ACCME CME credits, please contact Tara Shontz, RowanSOM Program Coordinator at email@example.com
For technical support with registration and access to the module, please contact the Rowan Online Marketplace Center submit an email ticket here.